135 related articles for article (PubMed ID: 22123108)
1. Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review.
Gonçalves D; Alves G; Soares-da-Silva P; Falcão A
Anal Chim Acta; 2012 Jan; 710():17-32. PubMed ID: 22123108
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
3. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
[TBL] [Abstract][Full Text] [Related]
4. Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: characterization of in vitro glucuronidation.
Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Almeida L; Wright LC; Soares-Da-Silva P
Drug Metab Dispos; 2006 Nov; 34(11):1856-62. PubMed ID: 16790555
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
6. Toxicology and safety of COMT inhibitors.
Haasio K
Int Rev Neurobiol; 2010; 95():163-89. PubMed ID: 21095462
[TBL] [Abstract][Full Text] [Related]
7. Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor.
Almeida L; Loureiro AI; Vaz-da-Silva M; Torrão L; Maia J; Fernandes-Lopes C; Falcão A; Igreja B; Wright L; Soares-da-Silva P
Curr Med Res Opin; 2010 May; 26(5):1097-108. PubMed ID: 20225994
[TBL] [Abstract][Full Text] [Related]
8. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.
Bonifácio MJ; Palma PN; Almeida L; Soares-da-Silva P
CNS Drug Rev; 2007; 13(3):352-79. PubMed ID: 17894650
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.
Marsala SZ; Gioulis M; Ceravolo R; Tinazzi M
Clin Neuropharmacol; 2012; 35(4):185-90. PubMed ID: 22805229
[TBL] [Abstract][Full Text] [Related]
10. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
Nissinen E
Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
[TBL] [Abstract][Full Text] [Related]
11. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.
Bonifati V; Meco G
Pharmacol Ther; 1999 Jan; 81(1):1-36. PubMed ID: 10051176
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of Parkinson's disease with COMT inhibitors].
Shabtai H; Korczyn A
Harefuah; 2001 Oct; 140(10):935-7. PubMed ID: 11681127
[No Abstract] [Full Text] [Related]
13. Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor.
Tsuji E; Okazaki K; Takeda K
Biochem Biophys Res Commun; 2009 Jan; 378(3):494-7. PubMed ID: 19056347
[TBL] [Abstract][Full Text] [Related]
14. L-dopa as substrate for human duodenal catechol-O-methyltransferase and aromatic L-amino acid decarboxylase.
Schultz E
Biomed Chromatogr; 1990 Nov; 4(6):242-4. PubMed ID: 2289048
[TBL] [Abstract][Full Text] [Related]
15. Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors.
Nissinen E; Männistö PT
Int Rev Neurobiol; 2010; 95():73-118. PubMed ID: 21095460
[TBL] [Abstract][Full Text] [Related]
16. Opicapone (Ongentys) - a COMT inhibitor for Parkinson's disease.
Med Lett Drugs Ther; 2021 Jan; 63(1615):3-5. PubMed ID: 33646998
[No Abstract] [Full Text] [Related]
17. What is the impact of catechol-O-methyltransferase (COMT) on Parkinson's disease treatment?
Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
Expert Opin Pharmacother; 2022 Jul; 23(10):1123-1128. PubMed ID: 35373688
[No Abstract] [Full Text] [Related]
18. Catechol-O-methyl transferase (COMT) inhibitors in patients with Parkinson's disease: is COMT genotype a useful indicator of clinical efficacy?
Rinne JO; Ulmanen I; Lee MS
Am J Pharmacogenomics; 2003; 3(1):11-5. PubMed ID: 12562212
[TBL] [Abstract][Full Text] [Related]
19. Catechol-O-methyltransferase and Parkinson's disease.
Tai CH; Wu RM
Acta Med Okayama; 2002 Feb; 56(1):1-6. PubMed ID: 11873938
[TBL] [Abstract][Full Text] [Related]
20. Development of characterization methods for entacapone in a pharmaceutical bulk.
Soukhova N; Kassymbek Z; Bradby S; Martin-Esker A; White P; Wahab S
J Pharm Biomed Anal; 2011 Mar; 54(4):860-5. PubMed ID: 21112716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
